GlobeNewswire

The Board of Directors of Talenom Plc resolved on the performance criteria and targets for the key employee incentive plans in the 2021–2023 performance period and on the issuance of option rights under the option rights 2021 plan

Share

Talenom Plc, Stock exchange release    20 May 2021 at 14:00 EEST

The Board of Directors of Talenom Plc resolved on the performance criteria and targets for the key employee incentive plans in the 2021–2023 performance period and on the issuance of option rights under the option rights 2021 plan

The Board of Directors of Talenom Plc has today resolved on the performance criteria and targets for the 2021–2023 performance period of the Performance Share Plan it established in February 2020 and the maximum number of shares to be issued. The Board of Directors has also resolved on the issuance of option rights to key employees in deviation from the pre-emptive subscription right. 

The aim of the incentive plans is to align the objectives of the shareholders and key employees to increase the value of the Company in the long term, commit the key employees to the Company and offer them competitive incentive schemes based on earning shares in the Company.

Performance Share Plan 2020–2024

On 25 February 2020, the Company announced that it had established a Performance Share Plan 2020–2024. The Performance Share Plan consists of three performance periods, covering the calendar years 2020–2022, 2021–2023 and 2022–2024. The Board of Directors resolves on the plan’s performance criteria and the targets to be set for each criterion at the beginning of each performance period.  

In the 2021–2023 performance period, the reward will be based on the Group’s net sales, operating profit and the execution of strategic projects. The rewards paid based on the performance period will correspond to the value of maximum total of 250,000 Talenom Plc shares, including also the proportion to be paid in cash. In the 2021–2023 performance period, approximately 85 persons are included in the target group of the Performance Share Plan, including the Company’s Executive Board members.

Thw potential reward based on the plan will be paid partly in the Company’s shares and partly in cash after the end of a performance period. The cash proportion is intended to cover taxes and tax-related expenses arising from the reward to a participant. As a rule, no reward is paid, if the participant’s employment or service ends before the reward payment. 

Each member of the Company’s Executive Board is obliged to hold at least 50 per cent of the net number of shares paid to them on the basis of the plan until the value of his or her shareholding in the Company is equal to the value of his or her gross annual salary. These shares must be held for as long as the person remains a member of the Executive Board.

Restricted Share Plan 2021

The Company has a valid Restricted Share Plan intended for selected key employees, including the Company’s Executive Board members. The reward from the Restricted Share Plan 2021 is based on a valid employment or service and the continuity of the employment or service during the vesting period and other possible terms imposed by the Board of Directors. 

The rewards in the period 2021–2023 will correspond to the value of a maximun total of 120,000 Talenom Plc shares, including also the proportion to be paid in cash. The reward is paid partly in the Company’s shares and partly in cash after the end of a 12–36-month vesting period. 

Option rights

The Board of Directors has resolved on the distribution of up to 600,000 option rights free of charge to 22 key employees of Talenom Group in accordance with the terms of Talenom Plc’s Option Rights 2021 plan. The terms are appended to this release. The resolution is based on an authorisation granted to the Board of Directors by the Annual General Meeting held on 3 March 2021. 

There is a weighty financial reason from the company's point of view to issue the option rights and deviate from the pre-emptive subscription right because the options are intended to form part of the incentive and commitment plan for key employees. 

The option rights will entitle their holders to subscribe to a total maximum of 600,000 new shares or shares held by the Company. The shares to be subscribed on the basis of the option rights now being issued account for a maximum total of 1.4 per cent of all shares in the Company and the votes conferred by the shares following the potential subscription if new shares are issued for the subscription.

The subscription period for shares subscribed using option rights is 1 March 2026–28 February 2027. The subscription price will be determined on the basis of the volume-weighted average price of the company’s shares on the issue date of the options. The subscription price for shares will be recorded in the Company’s invested unrestricted equity fund. 

TALENOM PLC
BOARD OF DIRECTORS

Further information:
Otto-Pekka Huhtala
CEO, Talenom Plc
tel. +358 40 703 8554
otto-pekka.huhtala@talenom.fi

Talenom is an agile and progressive accounting firm established in 1972. Our business idea is to make day-to-day life easier for entrepreneurs with the easiest-to-use digital tools on the market and highly automated services. In addition to comprehensive accounting services, we support our customers’ business with a wide range of expert services as well as financing and banking services. Our vision is to provide unbeatable accounting and banking services for SMEs.

Talenom has a history of strong growth – the average annual increase in net sales was approximately 15.5% between 2005 and 2020. At the end of 2020, Talenom had 912 employees in Finland and Sweden at a total of 47 locations. Talenom’s share is quoted on the main list of the Helsinki Stock Exchange.

DISTRIBUTION:
Nasdaq Helsinki
Main media
www.talenom.fi

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Developments portföljbolag Aprea Therapeutics uppnår primärt utfallsmått i kombinationsterapi av AML med eprenetapopt17.6.2021 10:25:55 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics rapporterar positiva resultat från en pågående fas 1/2-studie av bolagets läkemedelskandidat eprenetapopt i kombination med venetoklax och azacitidin i patienter med TP53-muterad akut myeloisk leukemi, AML. Studieresultaten visar att behandlingen uppnår studiens förutbestämda primära effektmått med fullständig remission i 37% av de utvärderade fallen. Studieresultaten baseras på en analys av 30 evaluerbara patienter där fullständig remission (CR) uppmättes i 37% av fallen. Den sammanlagda remissionsfrekvensen i kombination med ofullständig remission (CRi), CR/Cri, var 53%. Enligt studiens tillämpade design (Simon 2-stage) uppnåddes därmed det förutbestämda primära effektmåttet avseende fullständig remission. I den fortsatta delen av fas 1/2-studien ingår elva patienter som erhåller kombinationsterapin och monitoreras avseende säkerhet och behandlingse

Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia17.6.2021 10:25:55 CEST | Press release

STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2 study evaluating the efficacy of the company’s candidate drug eprenetapopt in combination with venteoclax and azacitidine in patients treated for TP53 mutated acute myeloid leukemia, AML. The results show that the primary efficacy endpoint of complete remission was reached in 37% of patients. The results are underpinned by an analysis performed on 30 evaluable patients, demonstrating complete remission in 37% of the cases. the composite response rate, i.e. CR combined with CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%. The pre-defined primary efficacy endpoint concerning complete remission was thus reached in accordance with the applied study design (Simon’s 2-stage). Eleven patients remain on the study treatment and is continuously monitored on safety and efficacy para

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.6.2021 10:10:00 CEST | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-06-17Loan192Coupon1.00 %ISIN-codeSE0010133207Maturity2023-03-15 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln1,600Volume bought, SEK mln800Number of bids2Number of accepted bids1Average yield-0.064 %Lowest accepted yield-0.064 %Highest yield-0.064 %% accepted at lowest yield 100.00 Auction date2021-06-17Loan1588Coupon1.50 %ISIN-codeSE0011063015Maturity2024-03-01 Tendered volume, SEK mln2,000 +/- 1,000 Volume offered, SEK mln5,500Volume bought, SEK mln2,000Number of bids6Number of accepted bids2Average yield0.032 %Lowest accepted yield0.031 %Highest yield0.034 %% accepted at lowest yield 62.50 Auction date2021-06-17Loan151 Coupon1.00 %ISIN-codeSE0013486156Maturity2030-06-12 Tendered volume, SEK mln700 +/- 350 Volume offered, SEK mln1,600Volume bought, SEK mln700Number of bids4Number of accepted bids3Average yield0.853 %Lowest accepted yield0.851 %Highest yield0.861 %% accepted at lowest yield 71.43 Auc

Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark17.6.2021 10:00:00 CEST | Press release

Press Release Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark Nokia to accelerate rollout following the availability of 3.5GHz spectrum; the enhanced services will offer premium 5G speeds to customers The move builds upon Nokia’s long-standing partnership with TTN as lead supplier of 5G RAN Radio 17 June 2021 Espoo, Finland – Nokia continues to build upon its ongoing business with leading Danish mobile operators, Telenor and Telia via their joint network (TTN) accelerating the delivery of 5G services nationwide following the availability of 3.5 GHz spectrum. Nokia is the exclusive supplier of 5G RAN and will support the modernization of the shared network ensuring TTN’s three million customers have the best connectivity experiences. The availability of spectrum in the 3.5GHz band will offer incredibly fast 5G speeds to customers. The modernization deal will focus initially on Denmark’s four largest cities before expanding to cover most Danish customers during 20

Share Buyback Transaction Details June 10 – June 16, 202117.6.2021 10:00:00 CEST | Press release

Share Buyback Transaction Details June 10– June 16,2021 June 17, 2021 - Wolters Kluwer today reports that it has repurchased 68,486of its own ordinary shares in the period from June 10, 2021, up to and including June 16, 2021, for €5.6million and at an average share price of €81.21. These repurchases are part of the share buyback program announced on February 24, 2021, under which we intend to repurchase shares for up to €350 million during 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 2,697,810191.971.13 For the period starting May 6, 2021, up to and including August 2, 2021, we have engaged a third party to execute €70 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are added to

Board of Directors Declares Share Buyback17.6.2021 08:33:39 CEST | Press release

17 June 2021 Board of Directors Declares Share Buyback On 16 June 2021, Acron’s Board of Directors resolved that the Company repurchase its outstanding shares as envisaged by clause 2, Article 72 of the Federal Law On Joint-Stock Companies. The number of shares sought shall not exceed 4,053,400, which is 10 per cent of the authorised capital. The repurchase price shall be RUB 6,050 per share. Therefore, the buyback amount shall not exceed RUB 24.5 billion. Shareholders may apply for repurchase from 8 July 2021 through 6 August 2021 inclusive. The repurchased shares shall be paid on or before 21 August 2021. If the total number of shares tendered by the Company’s shareholders exceeds 4,053,400, shares shall be repurchased from selling shareholders on a pro rata basis. A notification of the share buyback shall be posted on the Company’s website at https://www.acron.ru/en on or before 17 June 2021. Media contacts: Sergey Dorofeev Anastasia Gromova Tatiana Smirnova Public Relations Phone:

Eurocastle Announces 2021 AGM Results and PDMR Dealing Notification17.6.2021 08:00:00 CEST | Press release

Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Eurocastle Announces 2021 AGM Resultsand PDMR Dealing Notification Guernsey, 17 June 2021 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today announces the results of its 2021 Annual General Meeting held yesterday, 16 June 2021. All ordinary and extraordinary business tabled before the meeting in accordance with the Notice of Annual General Meeting circulated to shareholders on 26 May 2021 was approved. A copy of this Notice is available on Eurocastle’s website at www.eurocastleinv.com under Periodic Reports and Shareholder Communications in the Investor Relations Section. In addition the Company issued 1,000 ordinary shares to each of its three independent directors as part of their in-place compensation arrangements. By reference to its obligations under Article 19 of EU Regulation 596/2014, the Company is making public the following